An Observational Study of Avastin (Bevacizumab) in Patients With Glioblastoma Multiforme in First or Second Relapse
This single-arm, open-label, multicenter, observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in patients with glioblastoma multiforme in first or second relapse. Data will be collected from eligible patients initiated on Avastin treatment according to local label for up to 3 years.
Glioblastoma Multiforme
Progression-free survival at 6 months, approximately 3 years
Progression-free survival, approximately 3 years|Time to disease progression, approximately 3 years|Duration of objective response, approximately 3 years|Overall survival, approximately 3 years|Safety: Incidence of adverse events, approximately 3 years
This single-arm, open-label, multicenter, observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in patients with glioblastoma multiforme in first or second relapse. Data will be collected from eligible patients initiated on Avastin treatment according to local label for up to 3 years.